NEW YORK (GenomeWeb News) – Seegene and Selventa have entered into a collaborative agreement to develop molecular diagnostic products for "underserved markets" including autoimmune disease, cancer, and infectious diseases, the companies said today.

Under the partnership, the companies will combine Selventa's Systems Diagnostics "multi-omic analytics" platform with Seegene's qTOCE and DPO multiplex PCR chemistries to develop new molecular diagnostics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.